MiT family translocation renal cell carcinoma

Seminars in Diagnostic Pathology

Volumn 32, Issue 2, 2015, Pages 103-113

  Argani, Pedram ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chromosome translocation; Renal cell carcinoma; TFE3; TFEB

Indexed keywords

ANGIOLIPOMA; ARTICLE; CHROMOSOME TRANSLOCATION; CLEAR CELL PAPILLARY RENAL CELL CARCINOMA; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; EPITHELIOID ANGIOMYOLIPOMA; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CANCER; KIDNEY CARCINOMA; MELANOTIC XP11 TRANSLOCATION RENAL CANCER; OUTCOME ASSESSMENT; PAPILLARY RENAL CELL CARCINOMA; PERIVASCULAR EPITHELIOID CELL TUMOR; PRIORITY JOURNAL; T(6,11)RENAL CELL CARCINOMA; XP11 TRANSLOCATION PERIVASCULAR EPITHELIOID CELL TUMOR; XP11 TRANSLOCATION RENAL CELL CARCINOMA; CLASSIFICATION; GENE TRANSLOCATION; GENETICS; KIDNEY TUMOR; PATHOLOGY;

BASIC HELIX LOOP HELIX LEUCINE ZIPPER TRANSCRIPTION FACTOR;

BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS; TRANSLOCATION, GENETIC;

EID: 84925235649     PISSN: 07402570     EISSN: 19301111     Source Type: Journal    
DOI: 10.1053/j.semdp.2015.02.003     Document Type: Article

References (57)

1. Argani P., Antonescu C.R., Couturier J., et al. PRCC-TFE3 renal carcinomas: Morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t(X;1)(p11.2;q21). Am J Surg Pathol 2002, 26:1553-1566.
2. Argani P., Antonescu C.R., Illei P.B., et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol 2001, 159:179-192.
3. Ladanyi M., Lui M.Y., Antonescu C.R., et al. The der(17)t(X;17)(p11;q25) of human alveolar soft part sarcoma fuses the TFE3 transcription factor gene to ASPL, a novel gene at 17q25. Oncogene 2001, 20:48-57.
4. Clark J., Lu Y.J., Sidhar S.K., et al. Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene 1997, 15:2233-2239.
5. Argani P., Lui M.Y., Couturier J., Bouvier R., Fournet J., Ladanyi M. A novel CLTC-TFE3 gene fusion in pediatric renal adenocarcinoma with t(X;17)(p11.2;q23). Oncogene 2003, 22:5374-5378.
6. Argani P., Olgac S., Tickoo S.K., et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol 2007, 31:1149-1160.
7. Dijkhuizen T., van den Berg E., Wilbrink M., et al. Distinct Xp11.2 breakpoints in two renal cell carcinomas exhibiting X;autosome translocations. Genes Chromosomes Cancer 1995, 14:43-50.
8. Chian-Garcia C.A., Torres-Cabala C.A., Eyler R., et al. Renal cell carcinoma in children and young adults: a clinicopathologic and immunohistochemical study of 14 cases [abstract]. Mod Pathol 2003, (16):145A.
9. Bruder E., Passera O., Harms D., et al. Morphologic and molecular characterization of renal cell carcinoma in children and young adults. Am J Surg Pathol 2004, 28:1117-1132.
10. Altinok G., Kattar M.M., Mohamed A., Poulik J., Grignon D., Rabah R. Pediatric renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions and clinicopathologic associations. Pediatr Dev Pathol 2005, 8:168-180.
11. Ramphal R., Pappo A., Zielenska M., Grant R., Ngan B.Y. Pediatric renal cell carcinoma: Clinical, pathologic, and molecular abnormalities associated with the members of the MiT transcription factor family. Am J Clin Pathol 2006, 126:349-364.
12. Geller J.I., Argani P., Adeniran A., et al. Translocation renal cell carcinoma: lack of negative impact due to lymph node spread. Cancer 2008, 112:1607-1616.
13. Komai Y., Fujiwara M., Fujii Y., et al. Adult Xp11 translocation renal cell carcinoma diagnosed by cytogenetics and immunohistochemistry. Clin Cancer Res 2009, 15:1170-1176.
14. Zhong M., De Angelo P., Osborne L., et al. Dual color break-apart FISH assay on paraffin-embedded tissues as an adjunct to diagnosis of Xp11 translocation renal cell carcinoma and alveolar soft part sarcoma. Am J Surg Pathol 2010, 34:757-766.
15. Argani P., Laé M., Ballard E.T., et al. Translocation carcinomas of the kidney after chemotherapy in childhood. J Clin Oncol 2006, 24:1529-1534.
16. Rais-Bahrami S., Drabick J.J., De Marzo A.M., et al. Xp11 translocation renal cell carcinoma: delayed but massive and lethal metastases of a chemotherapy-associated secondary malignancy. Urology 2007, 70(178):e3-e6.
17. Parikh J., Wahid F., McCarville B. Translocation carcinoma of the kidney developing with a short latency period after cytotoxic chemotherapy for pediatric cancer. Mod Pathol 2014, 27(S2):252A.
18. Medeiros L.J., Palmedo G., Krigman H.R., Kovacs G., Beckwith J.B. Oncocytoid renal cell carcinoma after neuroblastoma: a report of four cases of a distinct clinicopathologic entity. Am J Surg Pathol 1999, 23:772-780.
19. Green W.M., Yonescu R., Morsberger L., et al. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service. Am J Surg Pathol 2013, 37:1150-1163.
20. Rao Q., Williamson S.R., Zhang S., et al. TFE3 break-apart FISH has a higher sensitivity for Xp11.2 translocation associated renal cell carcinoma compared with TFE3 or cathepsin K immunohistochemical staining alone: expanding the morphologic spectrum. Am J Surg Pathol 2013, 37:804-815.
21. Argani P., Hicks J., DeMarzo A., et al. Xp11 translocation renal cell carcinoma (rcc): extended immunohistochemical (IHC) profile emphasizing novel RCC markers. Am J Surg Pathol 2010, 34:1295-1303.
22. Argani P., Lal P., Hutchinson B., Lui M.Y., Reuter V.E., Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol 2003, 27:750-761.
23. Aulmann S., Longerich T., Schirmacher P., Mechtersheimer G., Penzel R. Detection of the ASPSCR1-TFE3 gene fusion in paraffin-embedded alveolar soft part sarcomas. Histopathology 2007, 50:881-886.
24. Mosquera J.M., Dal Cin P., Mertz K.D., et al. Validation of a TFE3 break-apart FISH assay for Xp11 translocation renal cell carcinomas. Diagn Mol Pathol 2011, 20:129-137.
25. Motyckova G., Weilbaecher K.N., Horstmann M., Rieman D.J., Fisher D.Z., Fisher D.E. Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci U S A 2001, 98:5798-5803.
26. Martignoni G., Pea M., Gobbo S., et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol 2009, 22:1016-1022.
27. Martignoni G., Gobbo S., Camparo P., et al. Differential expression of cathepsin-K in neoplasms harbouring TFE3 gene fusions. Mod Pathol 2011, 24:1313-1319.
28. Ross H., Martignoni G., Argani P. Renal cell carcinomas with clear cell and papillary features. Arch Path Lab Med 2012, 136:391-399.
29. Tickoo S.K., de Peralta-Venturina M.N., Harik L.R., et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 2006, 30:141-153.
30. Aydin H., Chen L., Cheng L., et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol 2010, 34:1608-1621.
31. Sukov W.R., Hodge J.C., Lohse C.M., et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol 2012, 36:663-670.
32. Ellis C.L., Eble J.N., Subhawong A.P., et al. Clinical heterogeneity of Xp11 translocation renal cell carcinoma: impact of fusion subtype, age and stage. Mod Pathol 2013 Dec 6, (Epub ahead of print).
33. Geller J.I., Dome J.S. Adjuvant therapy in pediatric patients with completely resected renal cell carcinoma. Pediatr Blood Cancer 2006, 46:527.
34. Meyer P.N., Clark J.I., Flanigan R.C., Picken M.M. Xp11.2 translocation renal cell carcinoma with very aggressive course in five adults. Am J Clin Pathol 2007, 128:70-79.
35. Argani P., Illei P., Netto G., et al. A distinctive subset of PEComas harbor TFE3 gene fusions. Am J Surg Pathol 2010, 34:1395-1406.
36. Tanaka M., Kato K., Gomi K., et al. Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma. Am J Surg Pathol 2009, 33:1416-1420.
37. Argani P., Aulmann S., Karanjawala Z., Fraser R.B., Ladanyi M., Rodriguez M.M. Melanotic Xp11 translocation renal cancers: a distinctive neoplasm with overlapping features of PEComa, carcinoma, and melanoma. Am J Surg Pathol 2009, 33:609-619.
38. Chang I.W., Huang H.Y., Sung M.T. Melanotic Xp11 translocation renal cancer: a case with PSF-TFE3 gene fusion and up-regulation of melanogenetic transcripts. Am J Surg Pathol 2009, 33:1894-1901.
39. Argani P., Hawkins A., Griffin C.A., et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol 2001, 158:2089-2096.
40. Srigley J.R., Delahunt B., Eble J.N., et al. The International Society of Urological Pathology (ISUP) Vancouver classification of renal neoplasia. Am J Surg Pathol 2013, 37:1469-1489.
41. Davis I.J., Hsi B.L., Arroyo J.D., et al. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A 2003, 100:6051-6056.
42. Kuiper R.P., Schepens M., Thijssen J., et al. Upregulation of the transcription factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas due to promoter substitution. Hum Mol Genet 2003, 12:1661-1669.
43. Smith N., Illei P., Allaf M., et al. t(6;11) renal cell carcinoma (RCC): expanded immunohistochemical profile emphasizing novel RCC markers and report of ten new genetically-confirmed cases. Am J Surg Pathol 2014, 38:604-614.
44. Argani P., Lae M., Hutchinson B., et al. Renal carcinomas with the t(6;11)(p21;q12): clinicopathologic features and demonstration of the specific Alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol 2005, 29:230-240.
45. Argani P., Yonescu R., Morsberger L., et al. Molecular confirmation of t(6;11)(p21;q12) renal cell carcinoma in archival paraffin-embedded material using a break-apart TFEB FISH assay expands its clinicopathologic spectrum. Am J Surg Pathol 2012, 36:1516-1526.
46. Rao Q., Liu B., Cheng L., et al. Renal cell carcinomas with t(6;11)(p21;q12): a clinicopathologic study emphasizing unusual morphology, novel Alpha-TFEB gene fusion point, immunobiomarkers, and ultrastructural features, as well as detection of the gene fusion by fluorescence in situ hybridization. Am J Surg Pathol 2012, 36:1327-1338.
47. Zhan H.Q., Wang C.F., Zhu X.Z., et al. Renal cell carcinoma with t(6;11) translocation: a patient case with a novel alpha-TFEB fusion point. J Clin Oncol 2010, 28:e709-e713.
48. Rao Q., Zhang X.M., Tu P., et al. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features. Int J Clin Exp Pathol 2013, 6:1452-1457.
49. Pan C.C., Sung M.-T., Huang H.-Y., Yeh K.-T. High chromosomal copy number alterations in Xp11 translocation renal cell carcinomas detected by comparative genomic hybridization are associated with aggressive behavior. Am J Surg Pathol 2013, 37:1116-1119.
50. Malouf G.G., Monzon F.A., Couturier J., et al. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 2013, 19:4673-4684.
51. Tsuda M., Davis I.J., Argani P., et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res 2007, 67:919-929.
52. Kobos R., Nagai M., Tsuda M., et al. Combining integrated genomics and functional genomics to dissect the biology of a cancer-associated, aberrant transcription factor, the ASPSCR1-TFE3 fusion oncoprotein. J Pathol 2013, 229:743-754.
53. Pflueger D., Sboner A., Storz M., et al. Identification of molecular tumor markers in renal cell carcinomas with TFE3 protein expression by RNA sequencing. Neoplasia 2013, 15:1231-1240.
54. Malouf G.G., Camparo P., Oudard S., et al. Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network. Ann Oncol 2010, 21:1834-1838.
55. Numakura K., Tsuchiya N., Yuasa T., et al. A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol 2011, 16:577-580.
56. Choueiri T.K., Mosquera J.M., Hirsch M.S. A case of adult metastatic Xp11 translocation renal cell carcinoma treated successfully with sunitinib. Clin Genitourin Cancer 2009, 7:E93-E94.
57. Antonescu C.R., Le Loarer F., Mosquera J.M., et al. Novel YAP1-TFE3 fusion defines a distinct subset of epithelioid hemangioendothelioma. Genes Chromosomes Cancer 2013, 52:775-784.